GlaxoSmithKline’s ‘much-needed’ Shingrix rebound has yet to materialize, analysts say

GlaxoSmithKline’s ‘much-needed’ Shingrix rebound has yet to materialize, analysts say

https://ift.tt/2XAjrqS

TrustVaccines

via FiercePharma: Vaccines https://ift.tt/2zKtXvv

September 16, 2021 at 09:55AM